{"url_path":"/sec/vate/8-k/2026-02-10/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-02-10","source_url":"https://www.sec.gov/Archives/edgar/data/1006837/0001006837-26-000005-index.html","accession_number":"0001006837-26-000005","cik":"0001006837","ticker":"VATE","issuer_name":"INNOVATE Corp.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1006837/0001006837-26-000005-index.html","primary_entity_key":"0001006837","primary_entity_name":"INNOVATE Corp."},"word_count":97,"has_tables":true,"body_markdown":"Item 8.01Other Events.\n\nOn February 10, 2026, the Company issued a press release titled \"Transdermal GFR Article Recognized as One of Five 2025 Editors’ Choice Articles by Journal of the American Society of Nephrology (JASN)”. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.\n\nExhibit 99.1 shall not be deemed filed for purposes of Section 18 of the Exchange Act, nor shall it be deemed incorporated by reference in any filing under the Securities Act, except as shall be expressly set forth by specific reference in a filing."}